Another extraordinary quarter for Emyria.

The strategic acquisition of the esteemed Pax Centre, coupled with our leading psychedelic-assisted therapy programs help amplify our impact in mental health care. The integration of Pax Centre operations with our Emerald Clinics network is expected to enhance patient outcomes, boost service revenues, and expand our Real-World Data capabilities.

Our exclusive licensing and commercialisation agreement with Aspen Pharmacare Australia is a testament to our drug development strategy and we continue to advance our promising novel MDMA analogues with partner, the University of Western Australia.

Moreover, our successful capital placement solidifies our finances. Read on to learn more and look our for an update on our drug development programs later in August!